Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms
Authors:
- 24 October 2011
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (3) , 441-444
Abstract
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) is a validated quality of life (QoL) instrument. In our Swedish cohort of 114 patients the symptomatic burden was found to be severe, with fatigue reported in 88% of the patients and reduced QoL in the majority of patients. Patients with primary myelofibrosis had the highest scores, low QoL, for most MPN-SAF items, compared to patients with polycythemia vera and essential thrombocythemia. Higher age showed significant associations with the BFI (Brief Fatigue Inventory) score, early satiety, concentration problems, dizziness, insomnia, cough and weight loss. Blood values, disease duration and myelosuppressive treatment did not significantly associate with any of the MPN-SAF items, with the exception of higher hemoglobin, which correlated with sad mood. Male patients with MPN scored significantly higher as regards sexual problems and weight loss compared to female patients. Overall, the MPN-SAF was found to be a valid instrument for assessing symptomatic burden among this population.Keywords
This publication has 15 references indexed in Scilit:
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patientsBlood, 2011
- Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemiaInternal and Emergency Medicine, 2009
- The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosisLeukemia Research, 2009
- AML transformation in 56 patients with Ph− MPD in two well defined populationsEuropean Journal of Haematology, 2009
- The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosisCurrent Hematologic Malignancy Reports, 2008
- Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disordersLeukemia, 2008
- The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)Cancer, 2006
- A phase II trial of pegylated interferon α‐2b therapy for polycythemia vera and essential thrombocythemiaCancer, 2006
- Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural AdaptationValue in Health, 2005
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993